Ciclosporin in the Treatment of Lupus Nephritis

Favre, H; Miescher, P; Huang, Yabing; Chatelanat, F; Mihatsch, Michael J.

doi:10.1159/000168040

Cited by 77 publications

(39 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since 1978, CSA has been successfully used for the prevention of graft rejection in patients who have received organ transplants. Moreover, in recent years it has been used with encouraging results in the treatment of various organ-and non-organ-specific autoimmune diseases (4)(5)(6)(7)(8)(9)(10).…”

mentioning

confidence: 99%

Long‐term treatment of systemic lupus erythematosus with cyclosporin A

Caccavo

Laganà

Mitterhofer

et al. 1997

Arthritis & Rheumatism

100

View full text Add to dashboard Cite

Objective. To evaluate the efficacy of long-term treatment with cyclosporin A (CSA) in systemic lupus erythematosus (SLE).Methods. Thirty patients with SLE whose condition was either poorly responsive or unresponsive to treatment with steroids and/or cytotoxic drugs were enrolled in a prospective, nonrandomized study of CSA. Patients with hypertension or hypercreatinemia were excluded. Disease activity was evaluated according to the systemic lupus activity measure. Assessments were made prior to study entry and after 6, 12, 18, and 24 months.Results. Twenty-seven patients completed at least 24 months of treatment with CSA. The mean disease activity score significantly decreased after 6 months of therapy (P < 0.01); this result was maintained throughout the study. A conspicuous steroid-sparing effect was observed following administration of CSA (P < 0.01).Side effects included hypertrichosis (63% of patients), paresthesias (23%), gastrointestinal symptoms (ZWo), gingival hyperplasia (17%), hypertension (lWo), tremors (7%), and nephrotoxicity (13%). No significant changes in serum creatinine levels were observed.Conclusion. CSA represents a helpful secondchoice treatment for patients with active SLE. Administration of CSA necessitates expert and careful followup of patients.Systemic lupus erythematosus (SLE), particularly in its severe form, still represents a major therapeutic Supported in part by a grant from Minister0

show abstract

mentioning

confidence: 99%

Long‐term treatment of systemic lupus erythematosus with cyclosporin A

Caccavo

Laganà

Mitterhofer

et al. 1997

Arthritis & Rheumatism

100

View full text Add to dashboard Cite

show abstract

“…Several uncontrolled studies have reported on the use of CSA in LN resistant to or intolerant of standard therapies (23)(24)(25). In an open randomized trial, 40 children with class III-V LN received either CSA or a combination of oral cyclophosphamide with corticosteroids for 1 year (26).…”

Section: Calcineurin Inhibitorsmentioning

confidence: 99%

Lupus Nephritis

Kalloo

Aggarwal

Mohan

2013

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

SummaryLupus nephritis (LN) remains a major cause of ESRD and is associated with a >4-fold increase in mortality and significant morbidity in patients with lupus. The treatment of LN has evolved significantly over the past decade due to data from well conducted randomized controlled trials. We are currently in an era in which effective regimens exist in the form of induction and maintenance agents. Histopathologic classification of LN remains one of the main factors guiding therapy.

show abstract

“…In patients resistant to corticosteroids and cylophosphamide, cyclosporin and gamma globulins have been. tried with variable success rates [16][17]. We did not use any of these drugs in our patients.…”

Section: Mjafl Vol 55 No2 1999mentioning

confidence: 99%

Lupus Nephritis-a Critical Analysis of 17 Patients

Prasher

Varma

Baliga

et al. 1999

Medical Journal Armed Forces India

View full text Add to dashboard Cite

Over a 3 year period from June 94 to June 97, out of 28 patients of systemic lupus, 17 were diagnosed as renal lupus. Demographic data showed 12 females and 5 males, mean age being 32.2 years (range 12 to 54 years). Mean time gap between presentation and definitive diagnosis was 32.4 days (7 days to 5 years). 2 patients (11.76%) presented renal lupus, one (5;88%) with acute interstitial lung disease and the remaining had the usual systemic manifestations of lupus. Anti dsDNA antibodies were positive in all patients while ANA was negative in 3 cases. Renal involvement consisted ofrapidly progressive glomerulonephritis in 2 patients (11.76%), nephrotic syndrome in 4 (23.52%) and non nephrotic range proteinuria in 11 (64.70%) patients. Mean serum creatinine at presentation was 2.4mg/dl (0.8mg/dl to 8.9 mg/dl). Three patients were dialysis dependent. Renal histology on light microscopy comprised of class II lesions in one (5.88%), class III in 4 (23.52%), class IV in 11 (64.70%-including one with crescents) and class V in one (5.88%) patient. All patients with advanced class IIIIIV lesions were treated with corticosteroids and cyclophosphamide pulses. Except one patient who died of pyopericardium all others improved and their serum creatinine stabilised around 2.3 mg/dl (0.8 to 4.6 mg/dl). The study highlights the importance of early diagnosis and aggressive management in this potentially treatable disease. MJAFI 1999; 55 : 126-128

show abstract

Ciclosporin in the Treatment of Lupus Nephritis

Cited by 77 publications

References 6 publications

Long‐term treatment of systemic lupus erythematosus with cyclosporin A

Long‐term treatment of systemic lupus erythematosus with cyclosporin A

Lupus Nephritis

Lupus Nephritis-a Critical Analysis of 17 Patients

Contact Info

Product

Resources

About